Cyclerion TherapeuticsInc. Stock News

Cyclerion Therapeutics Inc (CYCN) shares closed today at 1.3% above its 52 week low of $1.54, giving the company a market cap of $71M. The stock is currently down 45.8% year-to-date, down 46.8% over the past 12 months, and down 88.5% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 33.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 53.9% The company's stock price performance over the past 12 months lags the peer average by 49.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa

Cyclerion Therapeutics (NASDAQ:CYCN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and []

Zacks Investment Research upgraded shares of Cyclerion Therapeutics (NASDAQ:CYCN) from a hold rating to a buy rating in a report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $2.75 target price on the stock. According to Zacks, Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to []

Cubist Systematic Strategies LLC acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,084 shares of the companys stock, valued at approximately $67,000. A number of other institutional investors []

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Analysts at Cantor Fitzgerald lifted their FY2021 earnings per share estimates for Cyclerion Therapeutics in a report issued on Tuesday, November 23rd. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.70). Cantor Fitzgerald currently []

Cyclerion Therapeutics Inc. (NASDAQ:CYCN)s traded shares stood at 0.36 million during the last session. At the close of trading, the stocks price was $2.32, to imply an increase of 0.87% or $0.02 in intraday trading. The CYCN shares 52-week high remains $6.90, putting it -197.41% down since that peak but still an impressive 10.34% since Cyclerion Therapeutics Inc. (NASDAQ: CYCN) Has Succeeded To Excite In 2021, The Stock Is Down -24.18% Year-To-Date Read More »

JPMorgan Chase & Co. reduced its stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) by 43.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,786 shares of the companys stock after selling 46,316 shares during the quarter. JPMorgan Chase & Co.s holdings in Cyclerion Therapeutics were []

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.

Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with c

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical asses

Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting pot